{"status":"ok","message-type":"work","message-version":"1.0.0","message":{"indexed":{"date-parts":[[2026,9,1]],"date-time":"2026-09-01T03:14:25Z","timestamp":1788232465625,"version":"build-2803163510"},"reference-count":9,"publisher":"Elsevier BV","issue":"9","license":[{"start":{"date-parts":[[2025,9,1]],"date-time":"2025-09-01T00:00:00Z","timestamp":1756684800000},"content-version":"tdm","delay-in-days":0,"URL":"https:\/\/www.elsevier.com\/tdm\/userlicense\/1.0\/"},{"start":{"date-parts":[[2025,9,1]],"date-time":"2025-09-01T00:00:00Z","timestamp":1756684800000},"content-version":"tdm","delay-in-days":0,"URL":"https:\/\/www.elsevier.com\/legal\/tdmrep-license"},{"start":{"date-parts":[[2026,9,1]],"date-time":"2026-09-01T00:00:00Z","timestamp":1788220800000},"content-version":"vor","delay-in-days":365,"URL":"http:\/\/www.elsevier.com\/open-access\/userlicense\/1.0\/"}],"content-domain":{"domain":["jidonline.org","elsevier.com","sciencedirect.com"],"crossmark-restriction":true},"short-container-title":["Journal of Investigative Dermatology"],"published-print":{"date-parts":[[2025,9]]},"DOI":"10.1016\/j.jid.2025.03.012","type":"journal-article","created":{"date-parts":[[2025,4,22]],"date-time":"2025-04-22T23:27:29Z","timestamp":1745364449000},"page":"2120-2122","update-policy":"https:\/\/doi.org\/10.1016\/elsevier_cm_policy","source":"Crossref","is-referenced-by-count":3,"title":["One Step Closer to Personalized Dosing of Biologics in Psoriasis"],"prefix":"10.1016","volume":"145","author":[{"given":"Anke","family":"Eylenbosch","sequence":"first","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Jo L.W.","family":"Lambert","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]}],"member":"78","reference":[{"key":"10.1016\/j.jid.2025.03.012_bib1","doi-asserted-by":"crossref","first-page":"263","DOI":"10.1093\/ibd\/izz131","article-title":"Proactive infliximab drug monitoring is superior to conventional management in inflammatory bowel disease","volume":"26","author":"Fernandes","year":"2020","journal-title":"Inflamm Bowel Dis"},{"key":"10.1016\/j.jid.2025.03.012_bib2","doi-asserted-by":"crossref","DOI":"10.1093\/ecco-jcc\/jjab232.008","article-title":"OP09 proactive therapeutic drug monitoring is superior to standard treatment during maintenance therapy with infliximab; results from a 52-week multicentre randomised trial of 450 patients; the NOR-DRUM B study","volume":"16","author":"J\u00f8rgensen","year":"2022","journal-title":"J Crohns Colitis"},{"key":"10.1016\/j.jid.2025.03.012_bib3","doi-asserted-by":"crossref","DOI":"10.1016\/j.addr.2024.115421","article-title":"Model-informed precision dosing: state of the art and future perspectives","volume":"215","author":"Minichmayr","year":"2024","journal-title":"Adv Drug Deliv Rev"},{"key":"10.1016\/j.jid.2025.03.012_bib4","doi-asserted-by":"crossref","first-page":"837","DOI":"10.1080\/1744666X.2019.1630273","article-title":"Therapeutic drug monitoring with biologic agents in immune mediated inflammatory diseases","volume":"15","author":"Papamichael","year":"2019","journal-title":"Expert Rev Clin Immunol"},{"key":"10.1016\/j.jid.2025.03.012_bib5","doi-asserted-by":"crossref","first-page":"1708","DOI":"10.1016\/j.jid.2023.01.033","article-title":"Real-world implementation and outcomes of adalimumab therapeutic drug monitoring in psoriasis: a national specialized center experience","volume":"143","author":"Raharja","year":"2023","journal-title":"J Invest Dermatol"},{"key":"10.1016\/j.jid.2025.03.012_bib6","doi-asserted-by":"crossref","first-page":"145","DOI":"10.1080\/00365521.2020.1856405","article-title":"Efficacy of dashboard driven dosing of infliximab in inflammatory bowel disease patients; a randomized controlled trial","volume":"56","author":"Strik","year":"2021","journal-title":"Scand J Gastroenterol"},{"key":"10.1016\/j.jid.2025.03.012_bib7","doi-asserted-by":"crossref","first-page":"1309","DOI":"10.1007\/s40262-019-00759-z","article-title":"Population pharmacokinetics of risankizumab in healthy volunteers and subjects with moderate to severe plaque psoriasis: integrated analyses of phase I-III clinical trials","volume":"58","author":"Suleiman","year":"2019","journal-title":"Clin Pharmacokinet"},{"key":"10.1016\/j.jid.2025.03.012_bib8","doi-asserted-by":"crossref","first-page":"2251","DOI":"10.1016\/j.jid.2025.01.031","article-title":"Personalizing biologic therapy in psoriasis: development, validation, and user testing of a precision-dosing dashboard","volume":"145","author":"Thomas","year":"2025","journal-title":"J Invest Dermatol"},{"key":"10.1016\/j.jid.2025.03.012_bib9","doi-asserted-by":"crossref","first-page":"339","DOI":"10.1016\/j.det.2024.02.001","article-title":"Biologics for psoriasis","volume":"42","author":"Wride","year":"2024","journal-title":"Dermatol Clin"}],"container-title":["Journal of Investigative Dermatology"],"original-title":[],"language":"en","link":[{"URL":"https:\/\/api.elsevier.com\/content\/article\/PII:S0022202X25003756?httpAccept=text\/xml","content-type":"text\/xml","content-version":"vor","intended-application":"text-mining"},{"URL":"https:\/\/api.elsevier.com\/content\/article\/PII:S0022202X25003756?httpAccept=text\/plain","content-type":"text\/plain","content-version":"vor","intended-application":"text-mining"}],"deposited":{"date-parts":[[2026,9,1]],"date-time":"2026-09-01T02:58:13Z","timestamp":1788231493000},"score":1,"resource":{"primary":{"URL":"https:\/\/linkinghub.elsevier.com\/retrieve\/pii\/S0022202X25003756"}},"subtitle":[],"short-title":[],"issued":{"date-parts":[[2025,9]]},"references-count":9,"journal-issue":{"issue":"9","published-print":{"date-parts":[[2025,9]]}},"alternative-id":["S0022202X25003756"],"URL":"https:\/\/doi.org\/10.1016\/j.jid.2025.03.012","relation":{},"ISSN":["0022-202X"],"issn-type":[{"value":"0022-202X","type":"print"}],"subject":[],"published":{"date-parts":[[2025,9]]},"assertion":[{"value":"Elsevier","name":"publisher","label":"This article is maintained by"},{"value":"One Step Closer to Personalized Dosing of Biologics in Psoriasis","name":"articletitle","label":"Article Title"},{"value":"Journal of Investigative Dermatology","name":"journaltitle","label":"Journal Title"},{"value":"https:\/\/doi.org\/10.1016\/j.jid.2025.03.012","name":"articlelink","label":"CrossRef DOI link to publisher maintained version"},{"value":"simple-article","name":"content_type","label":"Content Type"},{"value":"\u00a9 2025 Society for Investigative Dermatology. Published by Elsevier Inc.","name":"copyright","label":"Copyright"}]}}